New IOL ideal for paediatric cataract procedures

Article

A novel, patented multi-component IOL (IVO Lens, InfinitVision Optics) allows for postoperative adjustments for changes in refraction, making it an ideal solution for paediatric cataract surgery, according to a recent report.

A novel, patented multi-component IOL (IVO Lens, InfinitVision Optics) allows for postoperative adjustments for changes in refraction, making it an ideal solution for paediatric cataract surgery, according to a report published in the January 2014 issue of the Journal of Refractive Surgery.

"Paediatric cataract surgery is essentially different from adult cataract surgery," wrote Dr Dimitra M. Portaliou and colleagues from the Institute of Vision and Optics at the University of Crete, Greece. "In paediatric cataract surgery, additional risks are present and postoperative complications may jeopardize and otherwise successful surgical intervention. One of the main considerations is the ongoing postoperative evolution of the power of IOL needed to correct children's eyes. A solution to the problem is provided by the development of the new, innovative, multicomponent InfiniteVision Optics IOL that will allow postoperative adjustments for postoperative changes in refraction," they wrote.

This lens remains adjustable throughout the patient’s lifetime, and allows for the addition and combination of presbyopic and astigmatic correction. It is comprised of two components: a base lens (posterior component) that has a platehaptic configuration, contains only spherical correction, and is implanted in a capsular bag, like a conventional posterior chamber IOL; and a front lens assembly with two haptics extending from the optic. These haptics have been designed to fit into two small bridges projecting off of the anterior surface of the base lens, securing both components together.

The front lens assembly allows for spherical, cylindrical, and multifocal primary corrections immediately and over time. The lens is implanted through a 1.8-mm to 2.8-mm incision, and is easily assembled inside the eye.

A feasibility study trial with the IVO lens included 6 eyes in 6 patients, with a mean age of 63.3 years. At 2 years' post-op, mean uncorrected visual acuity (from 9.11 to 0.68) and corrected distance visual acuity (from 0.28 to 0.83; P

For more information, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.